NVO - Novo Nordisk A/S

NYSE - Nasdaq Real Time Price. Currency in USD
48.3549
+1.0549 (+2.23%)
As of 2:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close47.3000
Open48.22
Bid48.3100 x 800
Ask48.3200 x 1800
Day's Range48.1100 - 48.6400
52 Week Range44.2800 - 58.3700
Volume1,485,609
Avg. Volume1,552,698
Market Cap119.829B
Beta0.82
PE Ratio (TTM)19.67
EPS (TTM)2.4580
Earnings DateN/A
Forward Dividend & Yield1.28 (2.63%)
Ex-Dividend Date2018-03-23
1y Target Est60.40
Trade prices are not sourced from all markets
  • Amazon, Novo Nordisk and Tesla are the Yahoo Finance charts of the day.
    Yahoo Finance Video6 days ago

    Amazon, Novo Nordisk and Tesla are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Amazon  (AMZN): Shares are up in early trade, at around .25%.  Amazon is adding a curbside pickup option at Whole Foods for Prime members. Shoppers will be able to order milk, eggs and other groceries on the Prime Now app and park in reserved spaces where workers will place the items in their cars. Novo Nordisk (NVO): Shares down here at 5.34%.  The Danish pharmaceutical company reported profit in line with forecasts for the second quarter, but the company said prices in the U.S, market would be lower next year. Tesla (TSLA): Shares down here, at around .68%. Tesla is on watch following Elon Musk's tweet Tuesday about possible plans to take the company private and reports of a $2 billion dollar investment in the Saudi Arabia investment fund. Members of the Tesla board said they have met "several times" to discuss Musk's desire to go private. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Novo Nordisk CEO Sees Demand for Better Products
    Bloomberg Video6 days ago

    Novo Nordisk CEO Sees Demand for Better Products

    Aug.08 -- Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European Open."

  • A Look at Novo Nordisk’s Human Insulin and Obesity Business
    Market Realist3 hours ago

    A Look at Novo Nordisk’s Human Insulin and Obesity Business

    In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.

  • How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018
    Market Realist5 hours ago

    How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018

    Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY (year-over-year) growth in local currencies in the first half of 2018 to 5.2 billion Danish kroner. That included revenues of 688 million Danish kroner, 856 million Danish kroner, 1.3 billion Danish kroner, and 1.9 billion Danish kroner in the United States, Europe, AAMEO (Africa, Asia, the Middle East, and Oceania), and China, respectively.

  • What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
    Market Realist5 hours ago

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.

  • Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
    Market Realist6 hours ago

    Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

    In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

  • Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
    Market Realistyesterday

    Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?

    Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.

  • Novo Nordisk: A Financial Overview after the First Half of 2018
    Market Realistyesterday

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.

  • The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
    Zacksyesterday

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

  • Novo Nordisk (NVO) Q2 2018 Earnings Conference Call Transcript
    Motley Fool4 days ago

    Novo Nordisk (NVO) Q2 2018 Earnings Conference Call Transcript

    NVO earnings call for the period ending June 30, 2018.

  • Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
    Zacks4 days ago

    Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

    Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

  • Eli Lilly Stock History
    Motley Fool4 days ago

    Eli Lilly Stock History

    Here's how this company became a biopharma giant, and what could be in store next for investors.

  • Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
    Zacks6 days ago

    Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

    Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

  • The Wall Street Journal6 days ago

    [$$] European Corporate Roundup for Wednesday

    It’s a busy day for earnings in Europe and Glencore notches a record profit on commodities recovery.

  • Associated Press6 days ago

    Novo Nordisk: 2Q Earnings Snapshot

    On a per-share basis, the Bagsvaerd, Denmark-based company said it had profit of 68 cents. The drugmaker posted revenue of $4.39 billion in the period. Novo Nordisk shares have declined slightly more than ...

  • Novo Nordisk CEO Sees Demand for Better Products
    Bloomberg6 days ago

    Novo Nordisk CEO Sees Demand for Better Products

    Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk, discusses the market reaction to earnings, drug prices in the U.S. and their M&A prospects. He speaks on "Bloomberg Markets: European ...

  • Financial Times7 days ago

    [$$] Shares in Novo Nordisk fall after warning on US price cuts

    The Danish pharma group is facing intensifying competition over prices — particularly in the US — and while negotiations with pharmacy benefit managers and managed care organisations were progressing, it expected average prices after rebates “to be lower compared with the levels in 2018”. Lars Fruergaard Jorgensen, chief executive, said sales growth in the first half of 2018 had been driven by “solid performance of our key innovative products” — Saxenda for obesity and Victoza, Tresiba and Xultophy for diabetes.

  • BMY vs. NVO: Which Stock Is the Better Value Option?
    Zacks7 days ago

    BMY vs. NVO: Which Stock Is the Better Value Option?

    BMY vs. NVO: Which Stock Is the Better Value Option?

  • Analysts’ Recommendations for Sanofi Stock before Q2 Results
    Market Realist19 days ago

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31. The company is a global pharmaceuticals player with products and therapies across the specialty areas of oncology, immunology, vaccines, multiple sclerosis, rare disease disorders, neurology, cardiovascular diseases, diabetes, and infectious diseases. As of July 25, according to a recent Reuters survey, two of the five analysts covering SNY stock have given it a “strong buy” recommendation, and three have rated it a “hold.” There are no “sell” ratings.

  • Novartis’s Key Developments in July
    Market Realist21 days ago

    Novartis’s Key Developments in July

    As we’ve already seen, Novartis (NVS) reported a 7% growth in operating revenues to ~$13.16 billion in Q2 2018. That compares to revenues of ~$12.24 billion in Q2 2017.

  • Novartis’s Q2 2018 Earnings: Sandoz
    Market Realist21 days ago

    Novartis’s Q2 2018 Earnings: Sandoz

    Sandoz, the generics arm of Novartis (NVS), is a market leader in differentiated generics. It reported nearly flat revenues at ~$2.46 billion during Q2 2018 compared to $2.45 billion during Q2 2017. Revenue growth was driven by a 2% favorable impact of foreign exchange, offset by a 2% decline in operating revenues.

  • Novartis in Q2 2018: Segment Performances
    Market Realist22 days ago

    Novartis in Q2 2018: Segment Performances

    As we saw in the previous part of this series, Novartis AG (NVS) surpassed Wall Street analysts’ estimates for Q2 2018 and reported revenues of ~$13.16 billion, a 7% growth YoY (year-over-year) compared to ~$12.2 billion in Q2 2017. Novartis AG, the holding company, provides healthcare solutions classified into the following three business segments: Innovative Medicines: prescription medicines Sandoz: generics Alcon: eye care

  • LLY vs. NVO: Which Stock Is the Better Value Option?
    Zacks26 days ago

    LLY vs. NVO: Which Stock Is the Better Value Option?

    LLY vs. NVO: Which Stock Is the Better Value Option?

  • CNBClast month

    Novozymes and Novo Nordisk sign deal to source power from Denmark’s largest wind farm

    The wind farm's 72 turbines will have a rotor diameter of 167 meters and weigh almost 900 tons each. The facility, located in the Baltic Sea, is set to be in full operation by the end of 2021. Novozymes and Novo Nordisk have signed an agreement to source power from Vattenfall’s Kriegers Flak offshore wind park, the Swedish utility said Friday.

  • Drugmakers Cancel Price Hikes After California Law Takes Effect
    Bloomberglast month

    Drugmakers Cancel Price Hikes After California Law Takes Effect

    A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.